The clinical information you need, at your fingertips.

Large real-world study suggests cardiovascular safety depends on whether testosterone is prescribed for documented hypogonadism. . .

First pan-PI3K/mTOR inhibitor expands targeted treatment options for patients without PIK3CA mutations. . .

Prospective study suggests prior anti-CGRP monoclonal antibody failure should not preclude a trial of preventive rimegepant. . .

Purified oral THC/CBD significantly reduced agitation within 2 weeks, with benefits sustained through 12 weeks in hospice-eligible patients with dementia. . .

Preclinical data suggest NTX-301 may overcome venetoclax resistance and target high-risk TP53-mutant disease by reactivating Hippo signaling. . .

Elevated plasma p-tau217 identified cognitively normal older adults at substantially higher risk for future cognitive impairment. . .